Psychedelic Longevity Hypothesis

Psychedelic longevity hypothesis is the source’s reframing of psychedelics from spiritual practice, recreation, or mental-health treatment into possible biological rejuvenation tools. In Bryan Johnson: I Just Took the Most Powerful Dose of DMT in the World… Here’s What It Was Like, Bryan Johnson connects psilocybin and 5-MeO-DMT to default-mode-network disruption, neuroplasticity, inflammation, glucose metabolism, microbiome shifts, and psychological flexibility.

The hypothesis is deliberately not stored as established fact. Johnson reports strong subjective effects and says prior psilocybin measurements looked promising, but he also says the 5-MeO-DMT objective data had not yet been analyzed. That makes the concept an example of Self-Experimentation under Tech-Culture Biohacking conditions, constrained by Medical Risk Management and evidence durability.

Key Claims

• The source’s novel move is to rank psychedelics beside sleep, exercise, sauna, metformin, rapamycin, and other longevity interventions.
• Brain rejuvenation is treated as harder than body-organ rejuvenation, making psychedelics attractive to Johnson as a brain-specific intervention.
• Anti-inflammatory, metabolic, microbiome, and connectivity claims remain source-scoped unless later evidence confirms them.
• The same intervention that might support flexibility can also cause Psychedelic Identity Disruption or acute psychiatric harm.

Connections

• Bryan Johnson, 5-MeO-DMT, and Psilocybin Mushrooms - source-specific substances and narrator.
• Default Mode Network and Neuroplasticity / 神经可塑性 - proposed brain mechanisms.
• Self-Experimentation, Tech-Culture Biohacking, and Medical Risk Management - evidence and safety boundaries.
• Mitochondrial Therapy, Patient-Derived Organoids, Cellular Reprogramming Control Problem, and GLP-1 agonists - broader longevity-intervention stack discussed in the same episode.